156 related articles for article (PubMed ID: 23531907)
1. [Indolent lymphomas: classification, clinical presentation and treatment]].
Zenhäusern R
Praxis (Bern 1994); 2013 Mar; 102(7):399-406. PubMed ID: 23531907
[TBL] [Abstract][Full Text] [Related]
2. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
3. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.
Servitje O; Muniesa C; Benavente Y; Monsálvez V; Garcia-Muret MP; Gallardo F; Domingo-Domenech E; Lucas A; Climent F; Rodriguez-Peralto JL; Ortiz-Romero PL; Sandoval J; Pujol RM; Estrach MT
J Am Acad Dermatol; 2013 Sep; 69(3):357-65. PubMed ID: 23796549
[TBL] [Abstract][Full Text] [Related]
5. Indolent nonfollicular lymphomas: characteristics, treatment, and outcome.
Coiffier B; Thieblemont C; Felman P; Salles G; Berger F
Semin Hematol; 1999 Apr; 36(2):198-208. PubMed ID: 10319388
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
7. [R.E.A.L. classification of non-Hodgkin lymphoma from the clinico-oncologic viewpoint].
Meusers P; Brittinger G
Praxis (Bern 1994); 1998 Jun; 87(23):793-800. PubMed ID: 9654985
[TBL] [Abstract][Full Text] [Related]
8. Small B-cell lymphomas of the lymph nodes and spleen: practical insights to diagnosis and pathogenesis.
Swerdlow SH
Mod Pathol; 1999 Feb; 12(2):125-40. PubMed ID: 10071338
[TBL] [Abstract][Full Text] [Related]
9. Purine analogue combinations for indolent lymphomas.
Di Bella N; Ravandi F
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S11-21. PubMed ID: 16549109
[TBL] [Abstract][Full Text] [Related]
10. [Lymphomas: new therapeutic options].
Weide R; Heymanns J; Thomalla J; Köppler H
MMW Fortschr Med; 2005 Jun; 147(24):28, 30-1. PubMed ID: 16001530
[TBL] [Abstract][Full Text] [Related]
11. A single unit lymphoma experience: outcome in a Cape Town academic centre.
Wood L; Robinson R; Gavine L; Juritz J; Jacobs P
Transfus Apher Sci; 2007 Aug; 37(1):93-102. PubMed ID: 17931976
[TBL] [Abstract][Full Text] [Related]
12. Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival.
Valli VE; Kass PH; San Myint M; Scott F
Vet Pathol; 2013 Sep; 50(5):738-48. PubMed ID: 23444036
[TBL] [Abstract][Full Text] [Related]
13. [Classification of non-Hodgkin's lymphomas on the basis of Morphological and immunological features shared by normal and neoplastic lymphatic cells (author's transl)].
Stein H
Immun Infekt; 1976 Apr; 4(2):52-69. PubMed ID: 1085745
[TBL] [Abstract][Full Text] [Related]
14. Indolent lymphomas other than follicular and marginal zone lymphomas.
Peinert S; Seymour JF
Hematol Oncol Clin North Am; 2008 Oct; 22(5):903-40, viii. PubMed ID: 18954743
[TBL] [Abstract][Full Text] [Related]
15. Can we cure indolent lymphomas?
Cabanillas F
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2655-9. PubMed ID: 10068269
[TBL] [Abstract][Full Text] [Related]
16. Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?
Tees MT; Flinn IW
Curr Treat Options Oncol; 2017 Mar; 18(3):16. PubMed ID: 28286923
[TBL] [Abstract][Full Text] [Related]
17. Outcome and prognostic factors in ocular adnexal lymphoma.
Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
[TBL] [Abstract][Full Text] [Related]
18. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome.
Tsang RW; Gospodarowicz MK; Pintilie M; Wells W; Hodgson DC; Sun A; Crump M; Patterson BJ
J Clin Oncol; 2003 Nov; 21(22):4157-64. PubMed ID: 14615444
[TBL] [Abstract][Full Text] [Related]
19. Non-Hodgkin lymphoma: diagnosis and treatment.
Ansell SM; Armitage J
Mayo Clin Proc; 2005 Aug; 80(8):1087-97. PubMed ID: 16092591
[TBL] [Abstract][Full Text] [Related]
20. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
